Praziquantel
Cysticercosis
Floatz Rating
BBB72/100
Confidence
Indicative
Sponsor
R-Evolution Worldwide S.r.l. Impresa Sociale
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06376396CT.gov Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis | — | Not Yet Recruiting | — | — | — |
NCT00441285CT.gov Neurocysticercosis: Combined Treatment With Praziquantel (PZQ) and Albendazole (ABZ) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cysticercosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Praziquantel (this asset) | R-Evolution Worldwide S.r.l. Impresa Sociale | Approved | BBB · 72 |
| Albendazole | R-Evolution Worldwide S.r.l. Impresa Sociale | P4 | BBB |
| [F-18]FBR | National Institute of Mental Health (NIMH) | P1 | CC |
| PBR28 | National Institute of Mental Health (NIMH) | P1 | CC |
| Dexasone | Johns Hopkins University | N/A | D |
| Phenytoin | Johns Hopkins University | N/A | D |
Other indications for Praziquantel
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Epilepsy | — | P2/3 | CCC · 55 |
| Schistosomiasis | — | N/A | D · 30 |
| Fibrotic Liver Disease | — | N/A | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Praziquantel in Cysticercosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/praziquantel-cysticercosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →